A Case Series of Rare Long-Term Bruising Following Injection of Liquid-Form Polycaprolactone: Mechanisms and Therapeutic Insights
Clinical, Cosmetic and Investigational Dermatology · 2026-01 · Volume 19 · 1-15
DOI: 10.2147/ccid.s571602 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2026-01. Verfasst von Hyeonseob Byeon und 12 weiteren Autor:innen. Beteiligte Einrichtung: BB Clinic Ginza, Tokyo, Japan. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Post-procedural bruising is one of the most common complications of aesthetic injections. Liquid-form polycaprolactone (PCL) is generally considered safe, with only transient and self-limiting adverse events reported. While bruising after liquid-form PCL injections is typically short-lived and no cases of permanent bruising have been documented, some patients may experience bruising persisting for several months. To date, however, no published reports have described such long-term cases. Here, we present retrospective review on seven clinical cases of persistent bruising following liquid-form PCL injections to the infraorbital, puncture point, and upper arm regions, and summarize their clinical management. Therapeutic approaches included pigment fragmentation (PICO, Nd:YAG, IPL, PDL), thermal loosening of the scaffold-tissue complex (radiofrequency, high-intensity focused ultrasound, warm application), mechanical dispersion (microcurrent stimulation, ultrasound, normal saline washout, gentle massage), and enzymatic degradation (hyaluronidase, lipase). All patients ultimately achieved resolution, and no serious adverse events were observed. These findings suggest that long-term bruising, although rare, is clinically relevant and may be associated with dense liquid-form PCL scaffold entrapment of pigment molecules or a Tyndall effect. Importantly, this phenomenon is not permanent, as its resolution parallels scaffold degradation over time. Preventive strategies, combined with multimodal management tailored to the underlying mechanisms, may reduce patient discomfort and optimize aesthetic outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- BB Clinic Ginza, Tokyo, Japan.
- BBC Omotesando, Tokyo, Japan.
- Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Obliv Clinic, Incheon, Republic of Korea.
- It's Me Clinic, Sejong, Republic of Korea.
- Chymber Clinic of Cosmetology, Odesa, Ukraine.
ORCID-Profile: Hyeonseob Byeon, Halim Baek, Vasanop Vachiramon, Youngjin Park, Kyungtae Bae, Kateryna Chymber, Jaeyun Jung, Xue Li, Seunghyeon Lee, Sheau Jye Teh, Olha Shestakova, Chanjong Lee, Rassapoom Sumaetheiwit
Zitieren
APA
Byeon, H., Baek, H., Vachiramon, V., Park, Y., Bae, K., Chymber, K., Jung, J., Li, X., Lee, S., Teh, S. J., Shestakova, O., Lee, C., & Sumaetheiwit, R. (2026). A Case Series of Rare Long-Term Bruising Following Injection of Liquid-Form Polycaprolactone: Mechanisms and Therapeutic Insights. Clinical, Cosmetic and Investigational Dermatology, Volume 19, 1-15. https://doi.org/10.2147/ccid.s571602
Vancouver
Byeon H, Baek H, Vachiramon V, Park Y, Bae K, Chymber K, et al. A Case Series of Rare Long-Term Bruising Following Injection of Liquid-Form Polycaprolactone: Mechanisms and Therapeutic Insights. Clinical, Cosmetic and Investigational Dermatology. 2026;Volume 19:1-15. doi:10.2147/ccid.s571602
BibTeX
@article{Byeon2026,
author = {Byeon, Hyeonseob and Baek, Halim and Vachiramon, Vasanop and Park, Youngjin and Bae, Kyungtae and Chymber, Kateryna and Jung, Jaeyun and Li, Xue and Lee, Seunghyeon and Teh, Sheau Jye and Shestakova, Olha and Lee, Chanjong and Sumaetheiwit, Rassapoom},
title = {A Case Series of Rare Long-Term Bruising Following Injection of Liquid-Form Polycaprolactone: Mechanisms and Therapeutic Insights},
journal = {Clinical, Cosmetic and Investigational Dermatology},
year = {2026},
volume = {Volume 19},
pages = {1--15},
doi = {10.2147/ccid.s571602}
}
EUVIMED